AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05271747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reuteri gotas
Description: Probiotic single-strain formulation containing Lactobacillus reuteri DSM17938 for 21 days, 5 drops/day before or after any daily meal.
Study NCT04244266 — intervention group
Intervention type: OTHER
Intervention: NO INTERVENTION, it is an observational study
Description: No intervention
Study NCT04092114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard of care (SOC) HIV prevention services in line with the South African DoH (Department of Health) PrEP (Pre-exposure Prophylaxis) rollout program that include daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine). In addition, risk reduction counseling, IPV (Intimate Partner Violence) screening using the VAWS (WHO Violence Against Women Survey) with referrals for counseling, medical care, or shelter assistance, among other care options, if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered
Study NCT04092114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHARISMA Intervention
Description: SOC (Standard of Care) per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable:~* Module A: General Partner Communication and Relationship Skills~* Module B: Partner Disclosure and Communication around PrEP Use~* Module C: Responding to Intimate Partner Violence and Safety Planning
Study NCT04044014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gellan sheet
Description: Gellan sheet.
Study NCT02036424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex
Description: intravitreal steroid
Study NCT02036424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: antiVEGF
Study NCT01532570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650
Description: TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
Study NCT03890393 — intervention group
Intervention type: DEVICE
Intervention: Electromyography
Description: Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.
Study NCT03057951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: once daily
Study NCT03057951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT02398773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02398773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT01921621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group B - Simulation Training
Description: Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
Study NCT01921621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group C - Proficiency Based Progression
Description: Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
Study NCT01461226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
Study NCT01461226 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
Study NCT04476719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATAFENOVIR 200 MG KAPSUL
Description: A 200 mg capsule 0ral administration with 240 ml water
Study NCT04476719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARBIDOL 100 MG KAPSUL
Description: Two 100 mg capsules will be administrated with 240 ml water orally.
Study NCT02327741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plavix
Description: taking plavix more than 12 months
Study NCT02327741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plavix
Description: taking plavix less than 12 months
Study NCT02548611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: see arm description
Study NCT02548611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: see arm description
Study NCT02180126 — intervention group
Intervention type: OTHER
Intervention: Follow-up
Description: Follow-up of of patients with borderline positive ANCA test results
Study NCT01059539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules.
Study NCT03227614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Person Intervention
Description: The patient participant will have a support person of her choice accompany her during her abortion procedure.
Study NCT04044014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gellan fluid gel
Description: Gellan fluid gel.
Study NCT04044014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepitel One
Description: Control dressing-- Mepitel One.
Study NCT01177124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR 6 Weeks Program
Description: MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program (Kabat-Zinn et al. 1985; Teasdale et al. 1995).
Study NCT03523689 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Undergo bronchoscopy
Study NCT03523689 — intervention group
Intervention type: PROCEDURE
Intervention: Radial Probe Endobronchial Ultrasound
Description: Undergo RP-EBUS
Study NCT04096105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: a single dose CC-93538 SC
Study NCT03563482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET scan
Description: Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment
Study NCT05014373 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Favipiravir + Standard of Care
Description: 1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care
Study NCT05014373 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir + Standard of Care
Description: 1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care
Study NCT05014373 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
Study NCT05014373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
Study NCT03395496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine pulpotomy agent
Study NCT03395496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProRoot (Aggregate)
Description: ProRoot MTA pulpotomy agent
Study NCT04548427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-352
Description: Eye Drop
Study NCT04548427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diquafosol Sodium 3%
Description: Eye Drop
Study NCT02746328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024 9 or 18 mg
Description: Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
Study NCT03783598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person centered, occupation based intervention support with problem solving therapy
Description: This program that was developed from the occupational therapy perspective which is person centered and occupation based for T2D intervention was designed as 6 modules. The intervention group received person centered, occupation based intervention support with problem solving therapy as 6 modules. The control group had not any intervention, just had a education about effect of diabetes on life.
Study NCT03256838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Description: Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.
Study NCT02565498 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Preoperative intensity modulated radiation therapy
Description: 50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
Study NCT05015647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LP group
Description: LP group patients replaced pasta, bread, biscuits etc. with low protein substitutes. We allowed them to consume more animal products than NP, preferring white meat to red meat and trying to limit cold cuts as much as possible. Furthermore, they were advised to prefer fresh or frozen fish, instead of dried or smoked one as well as to prefer fresh cheeses to seasoned ones. As for legumes, we advised to combine them with bread or normal cereals, for protein complementarity.
Study NCT05015647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NP group
Description: NP group was given the indication to try to eat the second dish only once a day or to split the portion of the second plate between lunch and dinner, if they wanted to keep the habit of making the meal complete. It was also given the indication to prefer, among protein sources, those of plant origin. We also indicated to alternate or replace cow's milk with plant substitutes such as: rice, almonds' or oats' drinks. Furthermore, we suggested to prefer white meat and to avoid offal and processed meat. Moreover, we indicated to substitute dried or smoked fish with fresh or frozen one.
Study NCT02916511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
Study NCT02916511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=2, ivgtt, d1, qw\*5
Study NCT02916511 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 1.8Gy/d, d1-5/week, 25Fx
Study NCT02168062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Receive individualized nutrition counseling
Study NCT02168062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive individualized symptom management service counseling
Study NCT02168062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Review educational modules
Study NCT02168062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive individualized exercise counseling
Study NCT02168062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC
Study NCT02168062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT02168062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02168062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02168062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given SC or IM
Study NCT02565498 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postoperative intensity modulated radiation therapy
Description: Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
Study NCT03347240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Lesioning
Description: Stereotactic radiofrequency lesioning of the pallidum or thalamus
Study NCT03347240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined anterior and posterior lumbosacral rhizotomy
Description: Combined anterior and posterior lumbosacral rhizotomy
Study NCT03347240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Bilateral DBS
Study NCT03347240 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-thecal baclofen infusion
Description: Intra-thecal Baclofen infusion
Study NCT03261063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evera MRI ICD System
Description: Subjects are implanted with Evera MRI ICD System and exposed to MRI environment per study requirements
Study NCT01567423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASAQ Winthrop® Sanofi Aventis
Description: Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
Study NCT01567423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem®, Novartis
Description: artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:~1. tab/dose for children 5 to 14.9 kg (total 6 tabs)~2. tabs/dose for children 15 to 24.9 kg (total 12 tabs)
Study NCT03844503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cereal Bar no fiber
Description: Cereal Bar no fiber
Study NCT03844503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cereal bar with 10 g fiber
Description: Cereal bar with 10 g fiber
Study NCT03844503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cereal bar with 20 g fiber
Description: Cereal bar with 20 g fiber
Study NCT02017821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high intensity aerobic training
Study NCT00810095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindFrame System
Description: Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
Study NCT02030665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Reinforcement provided contingent upon demonstration of negative drug tests
Study NCT02030665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Assessment & Treatment
Description: Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
Study NCT02030665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Treatment
Description: Standard psychoeducational approach to coping skills training
Study NCT04207268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gardening and Nutrition Advice
Description: Participate in gardening activities, gardening instructions and nutrition advice
Study NCT04207268 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Advice
Description: Participate in only nutrition advice
Study NCT04563819 — intervention group
Intervention type: GENETIC
Intervention: Genom-wide association study (GWAS) and biological pathway analyses
Study NCT02681185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Care
Description: Virtual Care consists of the following services and resources:~1. Have a virtual consult through online methods or telephone with one of the study endocrinologists~2. Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods~3. Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic~4. Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support.
Study NCT02681185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care offered in the patient's community. May involve in-person education at a diabetes centre and consultation with a healthcare professional.
Study NCT01060683 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hemoglobin determination + NaCl 0.9% bolus
Study NCT01060683 — intervention group
Intervention type: BIOLOGICAL
Intervention: hemoglobin determination + Venofundin bolus
Study NCT02515708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic Liver perfusion Device
Description: The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
Study NCT02515708 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Normothermic Liver perfusion Device
Description: The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
Study NCT03420443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat bran
Description: 45 g oat bran.
Study NCT03420443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat bran and blueberry husks
Description: 13 g freeze dried blueberry husks and 22 g oat bra + probiotic bacteria.
Study NCT03420443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: No oral supplementation
Description: No oral supplementation.
Study NCT00618995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ER niacin (+) laropiprant
Description: ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
Study NCT00618995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ER niacin
Description: ER niacin 2 g daily for 7 days.
Study NCT00618995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: laropiprant
Description: laropiprant 40 mg daily for 7 days.
Study NCT00618995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: matching placebo tablets for each of the interventions once daily for 7 days
Study NCT01535768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aqueous Suppressant Eye Drops
Description: Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)
Study NCT00387270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon 10 or 20 mg TID x 7 days
Study NCT03052387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assigned intervention
Description: \* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.~chin block graft~* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.~* Low vestibular incision exposing the symphysis area to the inferior border of the mandible.~* Using fissure bur to harvest the graft for the defect.~* Closure using vicryl 3-O sutures.